Windtree Therapeutics, Inc.
WINTW
Other OTC0.00
USD
+0.00
- -
CIK
0000946486
ISIN
US97382D1211
CUSIP
97382D303
Return %
Stock
S&P500
1Y
- -
19.01
3Y
-85.00
65.48
5Y
-98.85
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jed A. Latkin
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2600 Kelly Road Warrington PA United States of America 18976-3622
- IPO Date
- Aug 7, 1995
- CIK
- 0000946486
- Website
- windtreetx.com
- Similar Companies
- Business
- Windtree Therapeutics, Inc. (OTCID: WINTW) develops biopharmaceutical therapies targeting oncology and cardiovascular disorders with significant unmet medical needs; its lead product candidate, istaroxime, a first-in-class dual-mechanism SERCA2a activator and Na+/K+ ATPase inhibitor, advances in Phase 2b clinical trials for acute decompensated heart failure and early cardiogenic shock, demonstrating improvements in cardiac function, blood pressure, and renal profiles across three global Phase 2 studies; the cardiovascular portfolio further encompasses next-generation oral and intravenous SERCA2a activators in preclinical development for chronic and acute heart failure, including pure SERCA2a activators for heart failure with preserved ejection fraction, alongside rostafuroxin in Phase 2b for genetically associated hypertension; the oncology pipeline features a novel protein kinase C iota (aPKCi) inhibitor platform, acquired from Varian Biopharmaceuticals in April 2024, with potential topical and oral formulations under IND-enabling activities for rare and broad oncology indications; additional assets include AEROSURF, an aerosolized KL4 surfactant in Phase 2b for respiratory distress syndrome in premature infants, and Surfaxin, a lyophilized KL4 surfactant for respiratory conditions. Founded in 1992 and headquartered in Warrington, Pennsylvania, the company operates primarily in the United States with global and regional partnerships, including a licensing agreement with Lee's Pharmaceutical (HK) Ltd. for istaroxime and SERCA2a activators in Greater China, supporting a planned Phase 3 trial in acute heart failure, and a supply agreement with Evofem Biosciences Inc. (OTCQB: EVFM) for PHEXXI, a hormone-free contraceptive gel, to leverage manufacturing for cost reduction. Recent strategic shifts encompass a January 2025 corporate strategy announcement pursuing all-stock acquisitions of small companies with FDA-approved products for revenue generation; a June 2025 transformational agreement to acquire a revenue-generating environmental services business from Titan; stockholder approval in September 2025 for increasing authorized shares to 1 billion and pivoting toward environmental services alongside biotech partnerships; and ongoing efforts to out-license cardiovascular assets via New Growth Advisors while minimizing R&D expenses on the $1.25 billion market potential istaroxime program.